Description & Objectives
There is a need to provide physicians with an overview of the neurobiologic challenges of acute spinal cord injury, the current status of investigation for novel therapies that have been translated to human clinical trials, and the preclinical, scientific basis for each of these therapies. Clinicians will gain perspective on the challenges of translating research into human clinical trials and will be provided with the information they need to answer their patients questions about hoped-for neuroprotective and neurogenerative therapies for acute human spinal cord injury.
This conference is particularly targeted toward spine surgeons, orthopedic surgeons, anesthesiologists, and infectious disease physicians, as well as all other physicians interested in acute human spinal cord injury in the Pacific Northwest, Alaska, Hawaii and Canada.
At the conclusion of this lecture, the participant will provide better patient care through an increased ability to:
- Review past human trials of acute spinal cord injury to illustrate the challenges of translation in human spinal cord injury
- Discuss the distinctions between lab-based preclinical studies and human spinal cord injury that make translation difficult
- Outline strategies for facilitating successful translation of interventions for human spinal cord injury
Alexis Falicov, M.D., Course Chair
Jessica Martinson, MS, CME Manager
Rose Mullins, CME Specialist
Kate Purcell, Director of Corporate Relations and Major Gifts
Jim Santucci, Vice President of Operations
Theodore A. Wagner, M.D.